Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 71.7% during the third quarter, Holdings Channel reports. The fund owned 13,733 shares of the company’s stock after purchasing an additional 5,737 shares during the quarter. BNP Paribas Financial Markets’ holdings in Axsome Therapeutics were worth $1,234,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of AXSM. Comerica Bank increased its holdings in Axsome Therapeutics by 7,716.4% during the 1st quarter. Comerica Bank now owns 9,067 shares of the company’s stock worth $723,000 after purchasing an additional 8,951 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Axsome Therapeutics in the second quarter worth $2,735,000. Bank of New York Mellon Corp raised its holdings in Axsome Therapeutics by 7.7% in the second quarter. Bank of New York Mellon Corp now owns 165,564 shares of the company’s stock valued at $13,328,000 after acquiring an additional 11,793 shares in the last quarter. Peregrine Capital Management LLC boosted its stake in Axsome Therapeutics by 1.4% during the 2nd quarter. Peregrine Capital Management LLC now owns 87,373 shares of the company’s stock valued at $7,034,000 after acquiring an additional 1,238 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in Axsome Therapeutics by 5.1% during the 2nd quarter. Rhumbline Advisers now owns 54,931 shares of the company’s stock worth $4,422,000 after acquiring an additional 2,674 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 price target on shares of Axsome Therapeutics in a research note on Monday, September 16th. StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Wells Fargo & Company initiated coverage on Axsome Therapeutics in a research report on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $130.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, November 12th. Finally, HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Axsome Therapeutics in a report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $124.93.

Axsome Therapeutics Trading Down 0.3 %

Axsome Therapeutics stock opened at $99.76 on Tuesday. The firm has a 50-day moving average price of $92.63 and a two-hundred day moving average price of $86.92. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $105.00. The firm has a market capitalization of $4.83 billion, a price-to-earnings ratio of -15.28 and a beta of 1.18. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. During the same period in the previous year, the firm posted ($1.32) earnings per share. Sell-side analysts expect that Axsome Therapeutics, Inc. will post -4.6 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Mark E. Saad sold 11,016 shares of Axsome Therapeutics stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the sale, the director now directly owns 10,002 shares in the company, valued at $913,282.62. The trade was a 52.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 22.40% of the stock is currently owned by insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.